Status:
RECRUITING
Treatment of Desmoid Fibromatosis With Arterial Embolization
Lead Sponsor:
Istituto Ortopedico Rizzoli
Conditions:
Desmoid Fibromatosis
Eligibility:
All Genders
12+ years
Brief Summary
Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial emboliza...
Detailed Description
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive, characterized histologically by monoclonal myoblasts present in abundant stromal tissue.The current therapeutic strat...
Eligibility Criteria
Inclusion
- Patients of both sexes aged ≥ 12 years
- Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups)
- Patients not eligible for surgery or cryoablation
- Patients who have had embolization surgery for fibromatosis desmoide from 01/01/2023 to date and all new patients listed for this type of treatment.
- Signature of informed consent to the study
Exclusion
- Patients with life expectancy \<3 months or severely impaired status functional status (ASA 4)
- Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT)
- Patients with coagulation deficiency or plateletopenic disease
- Patients with documented active infection
- Incompatibility to performing MRI examination.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06945887
Start Date
July 1 2025
End Date
February 1 2029
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Ortopedico Rizzoli
Bologna, BO, Italy, 40136